Form 4: Roivant Sciences Insider Converts CVARs, Settles Taxes

Roivant Sciences President & CIO Mayukh Sukhatme converted Capped Value Appreciation Rights into common shares and subsequently settled tax obligations through share dispositions.

Summary

• Mayukh Sukhatme, President & CIO and Director of Roivant Sciences Ltd., converted 1,306,889 Capped Value Appreciation Rights (CVARs) into 58,391 common shares on March 30, 2026.
• The conversion occurred because the hurdle price of $11.5 per CVAR was satisfied, with the fair market value capped at $12.68 per share.
• Following the conversion, 29,809 common shares were disposed of at $26.41 on March 30, 2026, to satisfy tax withholding obligations related to the CVAR settlement.
• An additional 187,512 common shares were disposed of at $27.7 on March 31, 2026, for tax withholding obligations related to the vesting and settlement of previously granted Restricted Stock Units (RSUs).
• After these transactions, Mayukh Sukhatme beneficially owns 18,677,617 common shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the successful vesting of executive compensation and standard tax settlements, rather than a discretionary trade indicating strong bullish or bearish sentiment.

Positives

• The conversion of Capped Value Appreciation Rights (CVARs) into common shares indicates that the specified vesting and performance conditions were met, and the share price exceeded the hurdle price.
• The executive's beneficial ownership of 18,677,617 common shares after the transactions demonstrates significant alignment with shareholder interests.

Negatives

• A total of 217,321 common shares were disposed of through "net settlement" to cover tax withholding obligations, reducing the number of shares retained by the executive.

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the conversion of Capped Value Appreciation Rights (CVARs) and subsequent tax-related share dispositions are standard practices for executive compensation, particularly in the biotechnology and pharmaceutical sectors where long-term incentive plans often include equity-linked awards. These transactions reflect the vesting of previously granted compensation and the associated tax obligations, rather than discretionary trading based on market sentiment.

Comparison to Industry Standards

• The use of Capped Value Appreciation Rights (CVARs) and Restricted Stock Units (RSUs) as part of executive compensation packages is a common practice across the biotechnology and pharmaceutical industries, similar to compensation structures seen at companies like Moderna, Pfizer, and Johnson & Johnson, which often tie executive incentives to long-term share price performance and specific milestones.
• Net settlement of shares to cover tax withholding obligations upon the vesting and exercise of equity awards is a standard mechanism employed by most publicly traded companies to manage the tax implications for executives, aligning with practices observed at major tech and healthcare firms globally.

Stakeholder Impact

• Shareholders: The transactions reflect the vesting of executive compensation, aligning management's interests with long-term shareholder value, though the tax-related share sales slightly reduce the executive's direct holdings.
• Employees: The compensation structure involving CVARs and RSUs provides insight into the company's incentive programs for key personnel.

Key Dates

Recommendation

The filing details routine executive compensation vesting and tax-related share dispositions. These transactions are expected and do not signal a change in the company's fundamental outlook or the executive's long-term commitment. Therefore, a 'hold' recommendation is appropriate, as the filing provides no new information to warrant a change in investment thesis.

Keywords

Roivant Sciences, ROIV, Form 4, Insider Trading, Mayukh Sukhatme, Capped Value Appreciation Rights, CVARs, Restricted Stock Units, RSUs, Share Conversion, Tax Settlement, Beneficial Ownership